DK0804182T3 - Anvendelse af gabapentin ved behandling af angst og panik - Google Patents

Anvendelse af gabapentin ved behandling af angst og panik

Info

Publication number
DK0804182T3
DK0804182T3 DK95926249T DK95926249T DK0804182T3 DK 0804182 T3 DK0804182 T3 DK 0804182T3 DK 95926249 T DK95926249 T DK 95926249T DK 95926249 T DK95926249 T DK 95926249T DK 0804182 T3 DK0804182 T3 DK 0804182T3
Authority
DK
Denmark
Prior art keywords
treatment
gabapentin
anxiety
panic
terminal sequence
Prior art date
Application number
DK95926249T
Other languages
Danish (da)
English (en)
Inventor
Lakhbir Singh
Jason P Brown
Geoffrey Neil Woodruff
Nicolas S Gee
Original Assignee
Warner Lambert Co
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Priority claimed from US08/445,398 external-priority patent/US5792796A/en
Application filed by Warner Lambert Co filed Critical Warner Lambert Co
Application granted granted Critical
Publication of DK0804182T3 publication Critical patent/DK0804182T3/da

Links

Classifications

    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/185Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic or hydroximic acids
    • A61K31/19Carboxylic acids, e.g. valproic acid
    • A61K31/195Carboxylic acids, e.g. valproic acid having an amino group
    • A61K31/197Carboxylic acids, e.g. valproic acid having an amino group the amino and the carboxyl groups being attached to the same acyclic carbon chain, e.g. gamma-aminobutyric acid [GABA], beta-alanine, epsilon-aminocaproic acid or pantothenic acid
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00Drugs for disorders of the nervous system
    • A61P25/20Hypnotics; Sedatives
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00Drugs for disorders of the nervous system
    • A61P25/22Anxiolytics
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07KPEPTIDES
    • C07K14/00Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/46Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates
    • C07K14/47Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00Medicinal preparations containing peptides

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Organic Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Neurology (AREA)
  • Biomedical Technology (AREA)
  • Neurosurgery (AREA)
  • Biophysics (AREA)
  • Genetics & Genomics (AREA)
  • Toxicology (AREA)
  • Zoology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Biochemistry (AREA)
  • Anesthesiology (AREA)
  • Epidemiology (AREA)
  • Molecular Biology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Indole Compounds (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Hydrogenated Pyridines (AREA)
DK95926249T 1994-07-27 1995-07-11 Anvendelse af gabapentin ved behandling af angst og panik DK0804182T3 (da)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US28128594A 1994-07-27 1994-07-27
US08/445,398 US5792796A (en) 1994-07-27 1995-06-06 Methods for treating anxiety and panic
PCT/US1995/008702 WO1996003122A2 (fr) 1994-07-27 1995-07-11 Utilisation de la gabapentine dans le traitement de l'anxiete et de la panique

Publications (1)

Publication Number Publication Date
DK0804182T3 true DK0804182T3 (da) 2002-09-09

Family

ID=26960801

Family Applications (1)

Application Number Title Priority Date Filing Date
DK95926249T DK0804182T3 (da) 1994-07-27 1995-07-11 Anvendelse af gabapentin ved behandling af angst og panik

Country Status (18)

Country Link
EP (1) EP0804182B1 (fr)
JP (1) JPH10503490A (fr)
AT (1) ATE218334T1 (fr)
AU (1) AU703428B2 (fr)
CA (1) CA2193384C (fr)
CZ (1) CZ291757B6 (fr)
DE (1) DE69526972T2 (fr)
DK (1) DK0804182T3 (fr)
ES (1) ES2176334T3 (fr)
HU (4) HU0102041D0 (fr)
MX (1) MX9606674A (fr)
NZ (1) NZ290050A (fr)
PL (1) PL187064B1 (fr)
PT (1) PT804182E (fr)
RO (1) RO120041B1 (fr)
RU (1) RU2168982C2 (fr)
SK (1) SK283711B6 (fr)
WO (1) WO1996003122A2 (fr)

Families Citing this family (9)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5712158A (en) * 1995-06-06 1998-01-27 Warner-Lambert Company Cell line for the rapid expression of functional calcium channels
US6372792B1 (en) 1996-04-26 2002-04-16 Guy Chouinard Method for treating anxiety, anxiety disorders and insomnia
PL189872B1 (pl) 1996-07-24 2005-10-31 Warner Lambert Co Zastosowanie izobutylogaby i jej pochodnych do wytwarzania leku do leczenia bólu
HUP0004310A3 (en) 1997-10-27 2001-11-28 Warner Lambert Co Cyclic amino acids, and derivatives thereof and pharmaceutical compositions comprising the said compounds as active agents
EP1082306A1 (fr) * 1998-05-26 2001-03-14 Warner-Lambert Company Composes d'acide amines soumis a une contrainte de conformation et presentant une affinite pour la sous-unite alpha 2 delta d'un canal calcique
FR2781793B1 (fr) * 1998-08-03 2001-07-20 Prographarm Lab Procede de fabrication de granules de gabapentine enrobes
EP1214599A2 (fr) * 1999-09-16 2002-06-19 Warner-Lambert Company Criblage de ligands de liaison a la sous-unite alpha 2 delta-1
PL372210A1 (en) * 2002-02-22 2005-07-11 Warner-Lambert Company Llc Combinations of an alpha-2-delta ligand with a selective inhibitor of cyclooxygenase-2
RU2458049C2 (ru) * 2003-09-17 2012-08-10 Ксенопорт, Инк. Лечение или предупреждение синдрома беспокойных ног с использованием пролекарств аналогов гамк

Family Cites Families (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CA2016465A1 (fr) * 1989-06-02 1990-12-02 Zola Phillip Horovitz Methode de prevention ou de traitement de l'anxiete par l'emploi d'un bloqueur des canaux calciques
US5189026A (en) * 1991-06-07 1993-02-23 Fractal Laboratories, Inc. Treatment of human diseases involving dysregulation or dysfunction of the nervous system
HU222776B1 (hu) * 1992-05-20 2003-10-28 Northwestern University (S)-(+)-4-amino-3-(2-metil-propil)-butánsav előállításának új hexánsav- és butándisav-származék köztitermékei és ezek előállítása

Also Published As

Publication number Publication date
JPH10503490A (ja) 1998-03-31
CZ16297A3 (en) 1997-07-16
HU0102040D0 (en) 2001-07-30
HU223841B1 (hu) 2005-02-28
WO1996003122A3 (fr) 1996-07-18
CA2193384A1 (fr) 1996-02-08
SK9097A3 (en) 1998-05-06
HU0102041D0 (en) 2001-07-30
PL187064B1 (pl) 2004-05-31
PT804182E (pt) 2002-10-31
ATE218334T1 (de) 2002-06-15
NZ290050A (en) 1999-08-30
SK283711B6 (sk) 2003-12-02
CA2193384C (fr) 2002-03-19
DE69526972T2 (de) 2002-11-21
DE69526972D1 (de) 2002-07-11
HU0102043D0 (en) 2001-07-30
ES2176334T3 (es) 2002-12-01
MX9606674A (es) 1997-03-29
EP0804182A2 (fr) 1997-11-05
AU3006995A (en) 1996-02-22
AU703428B2 (en) 1999-03-25
EP0804182B1 (fr) 2002-06-05
RU2168982C2 (ru) 2001-06-20
WO1996003122A2 (fr) 1996-02-08
HUT76835A (en) 1997-11-28
CZ291757B6 (cs) 2003-05-14
PL318268A1 (en) 1997-05-26
RO120041B1 (ro) 2005-08-30

Similar Documents

Publication Publication Date Title
EA200000652A1 (ru) Кристаллы глюкагоноподобного пептида 1
ATE245416T1 (de) Neue fettanaloge zur behandlung von diabetes
BG102619A (en) Substituted n-[(aminoiminomethyl or aminomethyl) phenyl] propylamides
CO5690612A2 (es) Mimeticuerpos humanos centrales de la region de bisagra, mimeticos de la eritropoyetina, composiciones, metodos y usos
DE69027865D1 (de) ZUSAMMENSETZUNGEN enthaltend omega Conotoxin Peptide Derivate und deren Verwendung ZUR BEHANDLUNG VON ISCHÄMIE-ARTIGEN NEURONALEN SCHÄDIGUNGEN
ATE346934T1 (de) Modifizierte pflanzenviren als vektore für heterologe peptide
DK0804182T3 (da) Anvendelse af gabapentin ved behandling af angst og panik
DE3878231D1 (de) Neues cadiodilatin-fragment, prozess zu dessen herstellung und dessen anwendung.
AR002742A1 (es) Proteina reguladora del tipo adiposo, procedimiento para producir dicha proteina, formulaciones farmaceuticas que la incluyen, molecula de adn aisladaque codifica dicha proteina, vector y celulas recombinantes que comprenden dicho adn
ES548052A0 (es) Procedimiento para preparar peptidos
FI956055A0 (fi) Tekijä VII:sta johdettuja peptidejä
DE60139515D1 (de) Neue Polypeptide aus Bienengift und dessen Gebrauchsverfahren
MXPA02004505A (es) Peptidos mimeticos para epitope de apolipoproteinab-100 concatamero y peptidos modificados del mismo, y la composicion de vacuna que comprende los mismos.
DE60318749D1 (de) Paralytisches peptide von der spitzmaus sowie dessen nutzung in der therapie von neuromuskulären krankheiten
TR199700842T1 (xx) �nsan DNase I Varyantlar�.
ATE230027T1 (de) Menschliche dnase i varianten
DE3162674D1 (en) A purified polypeptide, a process for its preparation, its use and pharmaceutical compositions containing it
DK0539465T3 (da) Anvendelse af 20(R)-22-oxa-D-vitamin-analoger til fremstilling af et farmaceutisk præparat til behandling og/eller forebyggelse af hudaldring
ATE179989T1 (de) Peptide zur behandlung von allergien
WO1998029436A3 (fr) Peptides de lebetine utilises comme inhibiteurs de l'agregation plaquettaire
BG101847A (bg) Варианти на човешка дезоксирибонуклеаза i